This database contains 1231 studies, archived under the term: "humans"
Click here to filter this large number of results.
Effectiveness of an intervention in groups of family caregivers of dependent patients for their application in primary health centers. Study protocol
Rodriguez-Sánchez, Emiliano,
Mora-Simón, Sara,
Porras-Santos, Nieves,
Patino-Alonso, María C.,
Recio-Rodríguez, José I,
Becerro-Muñoz, Concepción,
Pérez-Arechaederra, Diana,
Gómez-Marcos, Manuel A,
García-Ortiz, Luis
Background: Although Primary Health Care (PHC) Teams are used to deal with prevention and treatment of sanitary problems in adults with chronic diseases, they usually have a lack of experience in development of psychotherapeutic interventions. However, these interventions are the ones that achieve better results to reduce symptomatology and improve emotional state of caregivers.The study […]
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
Quinn, Joseph F.,
Raman, Rema,
Thomas, Ronald G.,
Yurko-Mauro, Karin,
Nelson, Edward B.,
van Dyck, Christopher,
Galvin, James E.,
Emond, Jennifer,
Jack, Clifford R., Jr.,
Weiner, Michael,
Shinto, Lynne,
Aisen, Paul S
Context: Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.; Objective: To determine if supplementation with DHA slows cognitive and functional decline […]
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease
Penner, Jacob,
Rupsingh, Raul,
Smith, Matthew,
Wells, Jennie L.,
Borrie, Michael J.,
Bartha, Robert
Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD). The purpose of this study was to determine if galantamine treatment would result in detectable hippocampal metabolite changes that correlated with changes in cognition, as measured by the Mini-Mental State Examination […]
Effectiveness of a specific care plan in patients with Alzheimer’s disease: cluster randomised trial (PLASA study)
Nourhashemi, Fati,
Andrieu, Sandrine,
Gillette-Guyonnet, Sophie,
Giraudeau, Bruno,
Cantet, Christelle,
Coley, Nicola,
Vellas, Bruno
Objective: To test the effectiveness of a comprehensive specific care plan in decreasing the rate of functional decline in patients with mild to moderate Alzheimer’s disease compared with usual care in memory clinics.; Design: Cluster randomised trial.; Setting: 50 memory clinics in France.; Participants: Patients with Alzheimer’s disease (mini-mental state examination score 12-26). 1131 patients […]
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study
Muresanu, Dafin F.,
Alvarez, X. Anton,
Moessler, Herbert,
Novak, Philipp H.,
Stan, Adina,
Buzoianu, Anca,
Bajenaru, Ovidiu,
Popescu, Bogdan O.
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study. Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the […]
Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer’s disease
Matsuda, Osamu,
Shido, Emi,
Hashikai, Ayako,
Shibuya, Haruka,
Kouno, Mitsue,
Hara, Chizuko,
Saito, Masahiko
Background: Acetylcholinesterase inhibitors (i.e. donepezil) are known to benefit Alzheimer’s disease (AD) patients. However, the combined effects of acetylcholinesterase and cognitive stimulation therapy (CST) are still debated. The present study examined their combined effects on the progression of cognitive decline in AD.; Methods: The present study was a non-randomized controlled study and included two groups […]
EDUCA study: Psychometric properties of the Spanish version of the Zarit Caregiver Burden Scale
Martin-Carrasco, M.,
Otermin, P.,
Pérez-Camo, V.,
Pujol, J.,
Agüera, L.,
Martín, M. J.,
Gobartt, A. L.,
Pons, S.,
Balañá, M.
Objectives: The Zarit Caregiver Burden Scale, translated and validated into Spanish, is sensitive to the application of a Psychoeducational Intervention Program (PIP) for the prevention and reduction of burden in caregivers of Alzheimer’s disease (AD) patients (EDUCA study). The data obtained in EDUCA was used to reanalyse its psychometric properties and the cut-off points of […]
Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)
Objective: To evaluate, in a real-world clinical setting, the efficacy of rivastigmine in the management of six symptoms commonly associated with Alzheimer’s disease (AD).; Methods: This was a naturalistic, prospective, open-label, multi-centre, post-marketing, observational study. Data were collected by the participating study physicians at their practices across Canada. Subjects had a clinical diagnosis of mild-to-moderate […]
Comparative cardiovascular safety of dementia medications: a cross-national study
Fosbøl, Emil L.,
Peterson, Eric D.,
Holm, Ellen,
Gislason, Gunnar H.,
Zhang, Yinghong,
Curtis, Lesley H.,
Køber, Lars,
Iwata, Isao,
Torp-Pedersen, Christian,
Setoguchi, Soko
Objectives: To compare the cardiovascular safety of currently marketed dementia medications in new users in the United States and Denmark.; Design: Retrospective cohort study.; Setting: Nationally representative sample of Medicare beneficiaries from 2006 through 2009 and nationwide Danish administrative registries from 1997 through 2007.; Participants: Individuals treated with a dementia medication aged 65 and older.; […]